Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

(Reuters) -Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

Reporting zero taxable profits in the U.S. in 2019, Pfizer (NYSE:PFE) carried out possibly the largest tax-avoidance scheme ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Sen. Ron Wyden and other Democrats claim Pfizer used a "colossal" scheme to avoid paying billions in U.S. taxes.

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...